Charles River - JP Morgan Conference Presentation
DSA Segment
Drug discovery research, development, and regulatory-required safety
testing of potential new drugs
-
•
S
Discovery Services
Single source of services for discovering
and characterizing novel drug candidates
for preclinical development
Early discovery, in vivo and in vitro
capabilities
Expertise in most major therapeutic areas,
with a focus on oncology and CNS
Broad capabilities across small and large
molecule, antibody and C>
Expertise in integrated programs
Ability to engage with clients at any stage of
their discovery or early-stage development
programs
-
•
•
XX
Safety Assessment (SA)
Full suite of safety studies required for
regulatory submission on a global basis
across all therapeutic areas
Global leader in both non-regulated and
regulated (GLP) outsourced SA services
Broad scientific capabilities
General and specialty toxicology, bioanalysis,
pathology, safety pharmacology; drug
metabolism and pharmacokinetics (DMPK)
services
Largest specialty toxicology offering from
inhalation, and infusion to developmental and
reproductive toxicology
>95
Preclinical drug candidates
discovered for clients since 1999
40%
Outsourced SA market share, with
next largest competitor at 17%
-30
DSA sites worldwide ensures
proximity to clients
A safety assessment program costs
5x-10x less
than a late-stage clinical program,
providing incentive for clients to focus
R&D spending on IND achievement
Charles River - JP Morgan Conference Presentation
Note: CRL market share data based on management estimates and publicly available information.
11View entire presentation